Omvoh (mirikizumab) Letter of Medical Necessity
Omvoh (mirikizumab) is an IL-23 inhibitor for ulcerative colitis and Crohn's disease. Prior auth typically requires TNF inhibitor failure documentation and specific disease activity scoring.
FDA-Approved Indications
- ● moderately to severely active ulcerative colitis
- ● moderately to severely active Crohn's disease
Why Omvoh Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. Step therapy not completed (TNF inhibitor trial required)
- 2. Preferred IL-23 inhibitor on formulary (risankizumab or guselkumab)
- 3. Disease activity not adequately documented (Mayo score, CDAI)
- 4. Prior biologic failure documentation insufficient
What to Include in a Omvoh Letter of Medical Necessity
Document IBD diagnosis with endoscopic confirmation, disease activity scores (Modified Mayo for UC or CDAI for CD), prior biologic trials with dates, duration, and specific reason for failure/intolerance, current concomitant therapies, and lab work (CRP, fecal calprotectin).
Key clinical evidence to cite:
- ✓ LUCENT-1 and LUCENT-2 Phase 3 trials for UC
- ✓ VIVID-1 Phase 3 trial for Crohn's disease
Relevant guidelines:
- 📖 AGA 2024 IBD Treatment Guidelines
- 📖 ACG Clinical Guidelines for Ulcerative Colitis
Omvoh Prior Authorization Criteria
Standard criteria across major US payers for Omvoh. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Step therapy not completed (TNF inhibitor trial required)
- → Prior biologic failure documentation insufficient
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Omvoh
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Omvoh Prior Authorization FAQ
Why was my Omvoh prior authorization denied?
The most common denial reasons for Omvoh are: Step therapy not completed (TNF inhibitor trial required); Preferred IL-23 inhibitor on formulary (risankizumab or guselkumab); Disease activity not adequately documented (Mayo score, CDAI); Prior biologic failure documentation insufficient.
What should a Omvoh Letter of Medical Necessity include?
Document IBD diagnosis with endoscopic confirmation, disease activity scores (Modified Mayo for UC or CDAI for CD), prior biologic trials with dates, duration, and specific reason for failure/intolerance, current concomitant therapies, and lab work (CRP, fecal calprotectin).
Which payers cover Omvoh?
Omvoh is covered by major US payers including UnitedHealthcare, Aetna, Cigna, BCBS, Humana, though formulary tier and prior authorization criteria vary.